JP7237364B2 - 遺伝子治療 - Google Patents

遺伝子治療 Download PDF

Info

Publication number
JP7237364B2
JP7237364B2 JP2019542703A JP2019542703A JP7237364B2 JP 7237364 B2 JP7237364 B2 JP 7237364B2 JP 2019542703 A JP2019542703 A JP 2019542703A JP 2019542703 A JP2019542703 A JP 2019542703A JP 7237364 B2 JP7237364 B2 JP 7237364B2
Authority
JP
Japan
Prior art keywords
ids
sequence
apoeii
nucleic acid
mps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506714A (ja
JP2020506714A5 (enExample
Inventor
ブライアン ビガー
エレーヌ グレイツ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Publication of JP2020506714A publication Critical patent/JP2020506714A/ja
Publication of JP2020506714A5 publication Critical patent/JP2020506714A5/ja
Application granted granted Critical
Publication of JP7237364B2 publication Critical patent/JP7237364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019542703A 2017-02-07 2018-02-07 遺伝子治療 Active JP7237364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1701968.8A GB201701968D0 (en) 2017-02-07 2017-02-07 Gene therapy
GB1701968.8 2017-02-07
PCT/GB2018/050347 WO2018146473A1 (en) 2017-02-07 2018-02-07 Gene therapy

Publications (3)

Publication Number Publication Date
JP2020506714A JP2020506714A (ja) 2020-03-05
JP2020506714A5 JP2020506714A5 (enExample) 2021-03-25
JP7237364B2 true JP7237364B2 (ja) 2023-03-13

Family

ID=58462471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542703A Active JP7237364B2 (ja) 2017-02-07 2018-02-07 遺伝子治療

Country Status (6)

Country Link
US (2) US11701390B2 (enExample)
EP (2) EP3960188B1 (enExample)
JP (1) JP7237364B2 (enExample)
ES (2) ES2895263T3 (enExample)
GB (1) GB201701968D0 (enExample)
WO (1) WO2018146473A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
KR20250110842A (ko) 2022-11-01 2025-07-21 에라스무스 유니버시티 메디컬 센터 로테르담 대사질환을 위한 유전자 요법 구성체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513188A (ja) 2003-12-04 2007-05-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リソソーム蓄積症の処置のための組成物および方法
WO2016077356A2 (en) 2014-11-10 2016-05-19 Synageva Biopharma Corp. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108071A2 (en) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
RU2014126482A (ru) 2011-12-01 2016-01-27 Ангиочем Инк. Нацеленные соединения ферментов и их применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513188A (ja) 2003-12-04 2007-05-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リソソーム蓄積症の処置のための組成物および方法
WO2016077356A2 (en) 2014-11-10 2016-05-19 Synageva Biopharma Corp. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR THERAPY，2014年12月，VOL:22, NR:12，PAGE(S):2028 - 2037，http://dx.doi.org/10.1038/mt.2014.152
The J of Neuroscience, 2014, Vol.34, No.9, pp.3122-3129

Also Published As

Publication number Publication date
EP3579849B1 (en) 2021-09-08
EP3960188B1 (en) 2025-04-02
EP3960188A1 (en) 2022-03-02
WO2018146473A1 (en) 2018-08-16
JP2020506714A (ja) 2020-03-05
ES3035262T3 (en) 2025-09-01
US20200000854A1 (en) 2020-01-02
EP3579849A1 (en) 2019-12-18
US20230390340A1 (en) 2023-12-07
GB201701968D0 (en) 2017-03-22
US11701390B2 (en) 2023-07-18
ES2895263T3 (es) 2022-02-18

Similar Documents

Publication Publication Date Title
Gleitz et al. Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
JP6850736B2 (ja) ムコ多糖症治療用のアデノ随伴ウイルスベクター
JP6066902B2 (ja) 疾患の治療のためのベクター及び配列
Penon-Portmann et al. Current and new therapies for mucopolysaccharidoses
US20250188428A1 (en) Novel in vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced hscs for therapy of disorders
JP2021502105A (ja) タンパク質操作された細胞外小胞
TW201919676A (zh) 用於治療黏多醣病ｉｉ型之基因治療
US20230390340A1 (en) Gene therapy
JP2025087702A (ja) ヒト神経細胞又はグリア細胞により生産された組換えヒトイズロン酸－２－スルファターゼ（ｉｄｓ）によるムコ多糖症ｉｉ型の治療
Hurt et al. Mucopolysaccharidoses type I gene therapy
EP4285921B1 (en) Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
US20240342313A1 (en) Vector encoding rod-derived cone viability factor and human igk signal sequence
DE PONTI Exploring early therapeutic approaches in a Mucopolysaccharidosis type I (MPS I) mouse model
Consiglieri et al. Hematopoietic stem cell gene therapy of neurometabolic lysosomal storage diseases
JP2025538864A (ja) 代謝障害の遺伝子治療構築物
Russell Non-Genotoxic Anti-CD117 Conditioning for Hematopoietic Stem Cell Transplantation and Gene Therapy Applications
DAVIES et al. 28 Gene Therapy for Lung Diseases
He Modifying xenogeneic immune recognition and engraftment by genetic engineering
HK1253798B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
HK1253798A1 (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230221

R150 Certificate of patent or registration of utility model

Ref document number: 7237364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150